GHRP-6 Peptide

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that functions as a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). This G-protein coupled receptor was later identified as the endogenous receptor for ghrelin, making GHRP-6 one of the foundational tools in the discovery of the ghrelin/GHS-R signaling axis.

GHS-R1a Activation

Upon binding to GHS-R1a in the anterior pituitary and hypothalamus, GHRP-6 triggers Gq-coupled signaling, activating phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). The resulting increase in intracellular calcium drives somatotroph depolarization and growth hormone (GH) release. Reported EC50 values for GHRP-6 at GHS-R1a are in the low nanomolar range (~10 nM in heterologous expression systems).

Dual-Site Action: Pituitary and Hypothalamus

Unlike GHRH, which acts primarily on pituitary somatotrophs via the GHRH receptor (Gs/cAMP), GHRP-6 acts at two anatomical sites: it directly stimulates pituitary GH release and it activates hypothalamic neurons that suppress somatostatin tone while amplifying endogenous GHRH release. This dual mechanism produces synergistic GH pulses when GHRP-6 is co-administered with GHRH analogs such as CJC-1295 or sermorelin, an effect first characterized by Bowers and colleagues.

Appetite and Orexigenic Signaling

GHRP-6 robustly stimulates food intake in preclinical models through activation of GHS-R1a on neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus of the hypothalamus. This orexigenic signature distinguishes GHRP-6 from later-generation analogs such as ipamorelin, which were engineered to minimize appetite stimulation.

Secondary Effects on Cortisol and Prolactin

At supraphysiological doses, GHRP-6 produces modest increases in adrenocorticotropic hormone (ACTH), cortisol, and prolactin. These off-target effects are smaller than those of GHRP-2 and substantially larger than those of ipamorelin, which is essentially silent at the HPA axis in research models.

The following table summarizes the verified physicochemical and structural properties of GHRP-6 as confirmed through PubChem and primary literature sources. These data are essential for laboratory handling, reconstitution calculations, and analytical verification by HPLC or mass spectrometry.

The presence of two D-amino acid substitutions (D-Trp² and D-Phe⁵) is critical to the compound's resistance to proteolytic degradation by gastrointestinal and serum peptidases relative to all-L-amino acid analogs. The C-terminal lysine amide contributes to receptor binding affinity at GHS-R1a, while the histidine N-terminus and tryptophan residues are important for ghrelin-like receptor engagement. Researchers performing analytical verification typically observe a [M+H]⁺ peak at m/z 873.5 by ESI-MS, with characteristic UV absorbance at 280 nm reflecting the two tryptophan residues.

Proper handling and reconstitution of GHRP-6 are essential for preserving peptide integrity and ensuring reproducible results in research applications. The following protocol reflects standard laboratory practice for lyophilized hexapeptides containing tryptophan residues, which are susceptible to oxidation and light-induced degradation.

Reconstitution Protocol

1. Equilibrate the vial to room temperature for 20-30 minutes before opening to prevent atmospheric moisture condensation on the lyophilized powder.
2. Gently tap the vial to ensure all peptide powder is settled at the bottom prior to opening.
3. Select the reconstitution solvent. Bacteriostatic water (0.9% benzyl alcohol) is preferred for multi-use vials; sterile water or 0.9% saline are suitable for single-use preparations. Avoid pure DMSO.
4. Calculate target concentration. A common working concentration is 5 mg/mL: add 1.0 mL of solvent to a 5 mg vial. For 2 mg vials, 1.0 mL yields 2 mg/mL.
5. Add solvent slowly down the inner wall of the vial using a sterile syringe; do not inject directly onto the lyophilized cake.
6. Swirl gently to dissolve. Do not shake or vortex — mechanical agitation can denature the peptide and introduce foaming.
7. Allow 2-5 minutes for complete dissolution. The solution should appear clear and colorless.
8. Inspect for particulates. Any cloudiness or visible particles indicate incomplete dissolution or potential contamination.

Concentration Reference

• 5 mg vial + 1.0 mL solvent = 5 mg/mL (5,000 µg/mL)
• 5 mg vial + 2.0 mL solvent = 2.5 mg/mL (2,500 µg/mL)
• 2 mg vial + 1.0 mL solvent = 2 mg/mL (2,000 µg/mL)

Compound-Specific Handling Notes

GHRP-6 contains two tryptophan residues that are particularly susceptible to oxidative degradation when exposed to ambient light, elevated temperatures, or oxidizing solvent contaminants. Researchers should minimize exposure of reconstituted solutions to direct light and avoid repeated freeze-thaw cycles. Working aliquots should be prepared in amber or foil-wrapped vials when extended bench time is anticipated.

The peptide is acid-sensitive at extremes of pH; reconstitution solvents should remain near neutral pH (6.5-7.5). Avoid contact with strong acids, bases, or oxidizing agents. When transferring solutions, use low-protein-binding pipette tips to minimize peptide adsorption losses, particularly at sub-micromolar working concentrations.

All handling should be performed under aseptic conditions in a laminar flow hood when sterility is required. Document reconstitution date, solvent lot, and concentration on the vial label. This compound is intended strictly for in vitro and preclinical research use only.